Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.

[1]  M. Aapro,et al.  September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. , 2008, The oncologist.

[2]  C. Bokemeyer,et al.  Erythropoietins should be used according to guidelines. , 2008, The Lancet. Oncology.

[3]  C. Bokemeyer,et al.  The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines , 2008, Supportive Care in Cancer.

[4]  F. Morschhauser,et al.  [Management of anaemia in patient with cancer: results of the F-ACT study (French Anaemia Cancer Treatment)]. , 2007, Bulletin du cancer.

[5]  P. Johnston,et al.  Cancer-Related Anemia: Biological Findings, Clinical Implications and Impact on Quality of Life , 2005, Oncology.

[6]  C. Bokemeyer,et al.  EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. , 2004, European journal of cancer.

[7]  Dirk Schrijvers,et al.  The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. , 2004, European journal of cancer.

[8]  Allen R Nissenson,et al.  Anemia: not just an innocent bystander? , 2003, Archives of internal medicine.

[9]  L. Fallowfield,et al.  Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy , 2002, British Journal of Cancer.

[10]  S. Woolf,et al.  Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. , 2002, Blood.

[11]  Y. Brandberg,et al.  Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Caro,et al.  Anemia as an independent prognostic factor for survival in patients with cancer , 2001 .

[13]  E. Winer,et al.  Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Nortier,et al.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Kris,et al.  Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Ludwig,et al.  Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. , 1998, Seminars in oncology.

[17]  D. Cella,et al.  Factors influencing quality of life in cancer patients: anemia and fatigue. , 1998, Seminars in oncology.

[18]  C. Taylor,et al.  Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Aapro,et al.  Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study. , 2009, European journal of cancer.

[20]  M. Somerfield,et al.  Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Bokemeyer,et al.  EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. , 2007, European journal of cancer.